Lupus Trials News

The best and brightest are working toward finding better treatments and ultimately a cure for lupus. Read about how the most important influencers in the lupus community are effecting lupus research, along with other issues that matter most to you.

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […]

Lupus Therapeutics Collaborating with PPD to Accelerate Lupus Clinical Research

September 3, 2020 PPD, Inc. issued a press release  today announcing its collaboration with the Lupus Research Alliance affiliate Lupus Therapeutics to optimize lupus clinical research among its pharmaceutical and biotech clients. As a contract research organization, PPD helps its clients design and implement clinical trials. PPD expects to gain from Lupus Therapeutics’ deep clinical […]

23andMe Study Confirms Lupus Can Run in Families and Other New Insights

August 25, 2020 A study started four years ago and conducted by 23andMe provided many insights about lupus as a complex disease that is extremely difficult to diagnose and treat. While the survey of nearly 6,000 participants did not find new genetic factors causing lupus as hoped, the study confirmed that lupus can run in […]

Study Suggests Older Lupus Patients May Stop Hydroxychloroquine Without Raising Risk for Flares

August 18, 2020 A newly published study conducted by many of the research investigators who receive grant support from the Lupus Research Alliance found that older people with lupus may be able to discontinue their use of hydroxychloroquine. Investigators conducted this study because prolonged use of the drug can cause side effects like blurred vision […]

2018 LRA Lupus Insight Prize Recipient Receives $15 M Grant from NIH to Study Lupus Effects on the Brain

July 27, 2020 The Lupus Research Alliance congratulates 2018 Lupus Insight Prize recipient Betty Diamond, MD and the Feinstein Institutes for Medical Research on being awarded $15 million from the National Institute of Allergy and Infectious Disease to study brain dysfunction linked to lupus. Dr. Diamond will use the five-year grant to study a receptor […]

New Data Showed Safety and Effectiveness of Benlysta for Kids

July 27, 2020 A new international study published in Annals of the Rheumatic Diseases showed that belimumab (Benlysta) was safe and effective when given intravenously to children. In this Phase 2, randomized, placebo-controlled, blinded study, 93 patients 5-17 years of age received standard therapy plus either placebo or belimumab. As measured by commonly used tools, […]

LRA Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA

NEW YORK, NY. July 22. The Lupus Research Alliance congratulates Aurinia Pharmaceuticals Inc. on acceptance of its NDA filing and priority review designation by the U.S. Food and Drug Administration for its investigational drug voclosporin for lupus nephritis. A serious inflammation of the kidneys, lupus nephritis is one of the most common complications of systemic […]

Lupus Research Alliance Response to Janssen’s Ustekinumab Lupus Trial Discontinuation

June 26, 2020 The Lupus Research Alliance is disappointed at news from Janssen Pharmaceutical Companies of Johnson & Johnson that it has decided to discontinue the Phase 3 LOTUS study of ustekinumab (Stelara®) in Systemic Lupus Erythematosus (SLE). A Phase 3 trial presents data the U.S. Food and Drug Administration uses to decide whether or […]

New Study Presents Strategies That Helped African-Americans Take Part In Lupus Trials

June 22, 2020 African-Americans are more likely to develop lupus than Caucasians, but less likely to take part in clinical trials of the disease. However, a new study showed that several simple steps, such as providing transportation and flexible scheduling, may allow more African-Americans to participate in trials. The study was conducted by top lupus […]

Promising News from Major Medical Meeting, EULAR

Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. EULAR, the e-Congress of the European League Against Rheumatism, runs June 3 -6, and LRA is pleased to share promising results from clinical trials […]

Positive Data from Trial of Investigational Treatment KZR-616 for Lupus and Lupus Nephritis

June 3, 2020 Kezar Life Sciences, Inc. today announced updated results from the Phase 1b (Ph1b) portion of MISSION, a study testing the safety and tolerability of KZR-616 for people with systemic lupus erythematosus (SLE) and those who also have lupus nephritis. The drug showed effectiveness in improving seven measures of disease activity.  Both of […]

LRA Congratulates AstraZeneca on Positive Data on Anifrolumab Presented at Major Medical Meeting

June 3, 2020 The Lupus Research Alliance (LRA) is encouraged by positive data from two studies presented at the European League Against Rheumatism (EULAR) virtual annual congress on the use of the investigational medication anifrolumab as a potential treatment for people with lupus. Anifrolumab is a novel drug that works by blocking a group of […]

Aurinia Completes NDA and Requests Priority Review of Voclosoporin by FDA for Lupus Nephritis

May 28, 2020 The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application (NDA) to the U.S. FDA for voclosporin as a potential treatment for lupus nephritis with request for a priority review. Lupus nephritis is one of the most common complications of systemic lupus erythematosus, a serious […]

Lupus Research Alliance Encouraged by Lilly Looking at Potential Lupus Drug for COVID-19

April 23, 2020 The Lupus Research Alliance is pleased to share that Eli Lilly and Company entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to test the safety and effectiveness of its drug baricitinib as a potential treatment for hospitalized patients with COVID-19. An oral JAK1/JAK2 inhibitor, baricitinib is […]

Research Shows Benefit to Starting Belimumab Sooner Rather Than Later

April 16, 2020 Treating people with lupus earlier with belimumab (Benlysta) may work better than as a last option according to a study just published in the well-respected journal Arthritis & Rheumatology  Researchers in Italy analyzed data from 466 people with lupus at 24 centers in Italy who were receiving belimumab intravenously.  They looked at […]

LRA Salutes RemeGen on FDA Fast-Track Designation for Potential Lupus Treatment

April 16, 2020 The Lupus Research Alliance is pleased to share news that promises to speed up testing and review of a potential new treatment for lupus.  The U.S. Food and Drug Administration granted fast-track designation to RC18, in development by a company in China, RemeGen. The FDA defines fast track as “a process designed […]

Lupus Therapeutics, Affiliate of Lupus Research Alliance, Developing a Study Focused on Lupus Patients and COVID-19

  New York, NY, April 7, 2020 – Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance (LRA), announced today that it is embarking on a clinical study to assess the potential benefit of hydroxychloroquine and/or other lupus therapies in preventing or reducing the symptoms of COVID-19 in people with lupus. The study […]

Iguratimod as an Alternative Therapy for Resistant Lupus Nephritis

April 1, 2020 An investigational treatment, iguratimod showed positive results in an early clinical study of people with lupus nephritis that is refractory, meaning it has stubbornly resisted previous treatment with at least two immunosuppressants. Results were reported in Arthritis Research & Therapy. The small study included 14 patients with refractory lupus nephritis. Each were […]

Have You Thought About a Lupus Clinical Trial as a Treatment Option?

January 16, 2020 With so few current treatment options for lupus and lupus nephritis, patients may benefit from joining a clinical study. Right now, five national trials are testing interventions for lupus nephritis that you may be able to join. To learn more about these and over 150 other trials for lupus and its many […]

LRA Shares Excitement For What’s Ahead in Lupus Nephritis

January 16, 2020 Up to half of people with lupus will have lupus nephritis – damage to the kidneys that affects the ability to clear the body of wastes and toxins. In 2020, we expect to see significant progress in new drug development for lupus and lupus nephritis in particular with submissions for FDA approval in […]

LRA Celebrates Major Research Breakthroughs in 2019

January 7, 2020 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago. The past 12 months delivered many […]

Lupus Has Nerve Shows Large International Study

January 6, 2020 New research published in Arthritis and Rheumatology shows that peripheral nervous system (PNS) disease is an important part of neuropsychiatric lupus with significant effects on quality of life.  The peripheral nervous system is the network that sends signals between the brain and spinal cord (the central nervous system) with all the other […]

Positive Results on Anifrolumab for Lupus Published in New England Journal of Medicine

December 18, 2019 The Lupus Research Alliance (LRA) welcomes additional positive results published today in the New England Journal of Medicine online edition from AstraZeneca’s Phase 3 TULIP-2 trial studying the investigational biologic anifrolumab as a treatment for systemic lupus erythematosus (SLE or lupus).  The new study provides further details showing that anifrolumab, which targets […]

New Phase 3 Study Shows Positive Results for Benlysta® in Lupus Nephritis

December 17, 2019 The Lupus Research Alliance is thrilled to share exciting news from GSK that Benlysta (belimumab) demonstrated positive clinical trial results in treating lupus nephritis (LN), a common complication of lupus causing inflammation of the kidneys that can result in end-stage kidney disease. Called BLISS-LN, this Phase 3 trial is the largest one […]

Great News for Lupus Nephritis Treatment: Itolizumab Fast-Tracked by FDA

December 10, 2019 The Lupus Research Alliance (LRA) is pleased to share that a potential new treatment in development by Equillium, Inc. for lupus nephritis, itolizumab, was granted Fast Track designation by the U.S. Food and Drug Administration.  As defined by the FDA, this designation is “designed to facilitate the development, and expedite the review […]

End of content

No more pages to load